Drug Trial Radar · NCT03839771
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
968
Planned (sponsor's estimate)
Start
Mar 1, 2019
Primary completion
Apr 17, 2027
Study completion Sep 19, 2034
Sponsor
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Ulm
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AML and MDS-EB2 are malignancies of the bone marrow. The standard treatment for these diseases is chemotherapy. Patients participating have a special type of this disease because the leukemia cells (blasts) have developed an error in the genetic material (DNA). This error is called an IDH1 mutation or an IDH2 mutation (a mutation is a change in the DNA), which leads to changes in specific substances in the leukemia cells. This trial will investigate whether the addition of the new drugs Ivosidenib (for patients with IDH1 mutation) or Enasidenib (for patients with IDH2 mutation) to the standard treatment of chemotherapy controle the disease more effectively and for a longer period.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome With Excess Blasts-2
Interventions
AG-120Drug
250mg tablets
Placebo for AG-120Drug
250mg tablets
AG-221Drug
100mg tablets
Placebo for AG-221Drug
100mg tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: Approximately up to 60 months following first patient enrollment
Locations
181 sites in 15 countries. Site status is shown where the registry gives one.
AU-Adelaide-FLINDERS
Adelaide, Australia
AU-Adelaide-RAH
Adelaide, Australia
AU-Brisbane-PAH
Brisbane, Australia
AU-Camperdown-RPA
Camperdown, Australia
AU-Canberra-CANBERRAHOSPITAL
Canberra, Australia
AU-Douglas-TOWNSVILLE
Douglas, Australia
AU-Hobart TAS-RHOBART
Hobart, Australia
AU-Launceston TAS-LAUNCESTON
Launceston, Australia
AU-Melbourne-ALFRED
Melbourne, Australia
AU-Melbourne-AUSTIN
Melbourne, Australia
AU-Melbourne-MONASH
Melbourne, Australia
AU-Melbourne-RMELBOURNE
Melbourne, Australia
AU-Melbourne-SVHM
Melbourne, Australia
AU-Perth-FSH
Perth, Australia
AU-Perth-RPH
Perth, Australia
AU-Perth-SCGH
Perth, Australia
AU-Sydney-CONCORD
Sydney, Australia
AU-Sydney-RNSH
Sydney, Australia
AU-Sydney-SVHS
Sydney, Australia
AU-Sydney-WSAH
Sydney, Australia
AU-Waratah-CALVARYMATER
Waratah, Australia
AT-Graz-MEDUNIGRAZ
Graz, Austria
AT-Innsbruck-IMED
Innsbruck, Austria
AT-Linz-ORDENSKLINIKUM
Linz, Austria
AT-Vienna-HANUSCH
Vienna, Austria
BE-Antwerpen-ZNASTUIVENBERG
Antwerp, Belgium
BE-Brugge-AZBRUGGE
Bruges, Belgium
BE-Brussel-BORDET
Brussels, Belgium
BE-Brussel-UZBRUSSEL
Brussels, Belgium
BE-Bruxelles-STLUC
Brussels, Belgium
BE-Gent-UZGENT
Ghent, Belgium
BE-Haine-Saint-Paul-JOLIMONT
Haine-Saint-Paul, Belgium
BE-Hasselt-VIRGAJESSE
Hasselt, Belgium
BE-Leuven-UZLEUVEN
Leuven, Belgium
BE-Liege-CHRCITADELLE
Liège, Belgium
BE-Liege-CHULIEGE
Liège, Belgium
BE-Roeselare-AZDELTA
Roeselare, Belgium
BE-Yvoir-MONTGODINNE
Yvoir, Belgium
EE-Tartu-TARTU
Tartu, Estonia
FI-Helsinki-HUS
Helsinki, Finland
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.